Evidence map›Paper›PMID 40879249›Full record

ArticleInternational journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience2025

Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1.

Fen Zhao, Xizan Yue, Guangyu Wang, Hongwei Zhang

Abstract readCase Reports
In one paragraph

Article in International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Moyamoya Syndrome, Epilepsy and Hydrocephalus in Neurofibromatosis Type 1.International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fen ZhaoDepartment of Neurology, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.ORCID https://orcid.org/0000-0001-5643-4260
Xizan YueDepartment of Neurosurgery, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.
Guangyu WangDepartment of Neurosurgery, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.
Hongwei ZhangDepartment of Neurology, Children's Hospital Affiliated to Shandong University/Jinan Children's Hospital, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous syndrome. NF1-related vasculopathy represents a clinically significant yet underrecognized complication. Moyamoya syndrome, a rare cerebrovascular manifestation of NF1, has been rarely reported in the paediatric population. Epilepsy and hydrocephalus are also uncommon neurological manifestations of NF1. However, the co-occurrence of the above three symptoms in NF1 cases is rarely found.

methodsHere, we report a 2-year-old boy with moyamoya syndrome, epilepsy and hydrocephalus caused by de novo NF1 pathogenetic variants.

resultsHe experienced a 1-week history of paroxysmal hands weakness and frequent seizures. Physical examination showed macrocephaly (head circumference was 52 cm), reduced distal muscle strength in both upper limbs (grade III) and the presence of 6 or more café-au-lait macules (CALMs). Brain magnetic resonance imaging (MRI) showed moyamoya syndrome and hydrocephalus. Electroencephalographic (EEG) monitored two episodes of electrical persistent seizures and one focal motor seizure. Trio whole exome sequencing (Trio-WES) demonstrated a de novo and heterozygous NF1 missense mutation (c.5488C > G, p. Arg1830Gly). The final diagnoses were 'neurofibromatosis type 1, moyamoya syndrome, epilepsy, and hydrocephalus'. Following surgical intervention and treatment with levetiracetam, the patient achieved normal muscle strength and was seizure-free.

conclusionWhen articles about complications of NF1 are placed in a separate category, little is written about NF-1-related moyamoya syndrome, hydrocephalus and epilepsy simultaneously. This report describes a case of NF1 with moyamoya syndrome combined with hydrocephalus and epilepsy, which could enhance clinicians' understanding of the neurological manifestations of NF1 and provide reference value for clinical practice.

Indexed as

EpilepsyHydrocephalusMoyamoya DiseaseNeurofibromatosis 1Child, PreschoolElectroencephalographyHumansMagnetic Resonance ImagingMaleNeurofibromin 1Neurofibromin 1hydrocephalusepilepsymoyamoya syndromeneurofibromatosis type 1

Identifiers

PMID40879249
PMCPMC12320758

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.